Laurus Labs in focus as USFDA inspection ends

| Updated on November 21, 2019


Laurus Labs on Thursday said the US drug authority USFDA has completed the pre-approval inspection for an API manufactured at its units 1 & 3, at JN Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature.

“No data integrity issues were observed in the inspection,” it further said. The inspection was carried out from November 18-21.

The stock may remain in focus, as investors will follow further developments.

Published on November 21, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like